HC Wainwright restated their buy rating on shares of Syndax Pharmaceuticals (NASDAQ:SNDX – Free Report) in a report published ...

Equities research analysts at HC Wainwright issued their Q1 2025 earnings per share estimates for shares of Syndax ...

Investing.com – U.S. stocks were lower after the close on Wednesday, as losses in the Technology, Financials and Basic Materials ...

NEW YORK, March 05, 2025 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today ...

Syndax Pharmaceuticals , Inc. (Nasdaq: NASDAQ:SNDX) today announced that data from the Phase 1 portion of the ongoing Phase 1/2 ...

After hours: March 11 at 6:43:55 PM EDT Loading Chart for SNDX ...

After hours: March 7 at 6:38:22 p.m. EST ...